Shanxi Xinyu Pharmaceutical Co. Ltd.

Primary objective: To conduct a formal bioequivalence test using the benidipine hydrochloride tablets of Shanxi Xinyu Pharmaceutical Co., Ltd. as the test preparation and the benidipine hydrochloride tablets certified by Kyowa Kirin Co., Ltd as the reference preparation. Secondary objective: To study the safety of the test preparation benidipine hydrochloride tablets and the reference preparation benidipine hydrochloride tablets in healthy adult subjects

Main purpose: Use nicorandil tablets from Shanxi Xinyu Pharmaceutical Co., Ltd. as the test preparation; and use nicorandil tablets from Chugai Co., Ltd. as the reference preparation to conduct relative bioavailability and bioequivalence in humans. sexual evaluation.

Main study objectives: To investigate the relative bioavailability of single-dose oral (fasting/postprandial) test preparation Olmesartan medoxomil amlodipine tablets [Specification: each tablet contains 20 mg of Olmesartan medoxomil and 5 mg of amlodipine besylate (calculated as amlodipine), produced by Shanxi Xinyu Pharmaceutical Co., Ltd.] and reference preparation Olmesartan medoxomil amlodipine tablets [trade name: Siweika®, specification: each tablet contains 20 mg of Olmesartan medoxomil and 5 mg of amlodipine besylate (calculated as amlodipine), produced by Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd.] in healthy Chinese subjects, analyze the pharmacokinetic parameters of the two preparations, evaluate the bioequivalence of the two preparations, and provide a reference for the application and clinical use of the drug. Secondary study objectives: To evaluate the safety of single oral fasting and postprandial test preparations and reference preparations in healthy Chinese adult subjects.